Daniel Y C Heng

Daniel Y C Heng

UNVERIFIED PROFILE

Are you Daniel Y C Heng?   Register this Author

Register author
Daniel Y C Heng

Daniel Y C Heng

Publications by authors named "Daniel Y C Heng"

Are you Daniel Y C Heng?   Register this Author

100Publications

2954Reads

40Profile Views

The evolving role of cytoreductive nephrectomy in metastatic renal cell carcinoma.

Curr Opin Urol 2019 Sep;29(5):507-512

Department of Oncology, University of Calgary, Tom Baker Cancer Centre, Calgary, Alberta, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MOU.0000000000000657DOI Listing
September 2019

Sequencing and Combination of Systemic Therapy in Metastatic Renal Cell Carcinoma.

Eur Urol Oncol 2019 Sep 1;2(5):505-514. Epub 2019 Aug 1.

Institut Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2019.06.022DOI Listing
September 2019

An Update on Predictive Biomarkers in Metastatic Renal Cell Carcinoma.

Eur Urol Focus 2019 Apr 19. Epub 2019 Apr 19.

Division of Medical Oncology, Department of Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, Canada. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S24054569193011
Publisher Site
http://dx.doi.org/10.1016/j.euf.2019.04.004DOI Listing
April 2019

Prognostication in Kidney Cancer: Recent Advances and Future Directions.

J Clin Oncol 2018 Oct 29:JCO2018790147. Epub 2018 Oct 29.

Jeffrey Graham and Daniel Y.C. Heng, University of Calgary, Calgary, Alberta; and Shaan Dudani, University of Ottawa, Ottawa, Ontario, Canada.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2018.79.0147
Publisher Site
http://dx.doi.org/10.1200/JCO.2018.79.0147DOI Listing
October 2018

First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.

Eur Urol 2018 09 13;74(3):309-321. Epub 2018 Apr 13.

Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada; Division of Urology, Department of Surgery, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2018.03.036DOI Listing
September 2018

Real-world Outcomes in Advanced Urothelial Cancer and the Role of Neutrophil to Lymphocyte Ratio.

Clin Genitourin Cancer 2018 06 29;16(3):e637-e644. Epub 2017 Dec 29.

Tom Baker Cancer Centre, Department of Oncology, University of Calgary, Calgary, AB, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2017.12.009DOI Listing
June 2018

Personalized Management of Advanced Kidney Cancer.

Am Soc Clin Oncol Educ Book 2018 May;38:330-341

From the Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada; Kidney Cancer Program, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX; Karmanos Cancer Institute, Wayne State University, Detroit, MI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/EDBK_201215DOI Listing
May 2018

Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial.

J Clin Oncol 2018 03 29;36(8):757-764. Epub 2018 Jan 29.

David Cella, Northwestern University Feinberg School of Medicine, Chicago, IL; Bernard Escudier, Institut Gustave Roussy, Villejuif; Florence Marteau, Ipsen Pharma, Boulogne-Billancourt; Paul Williams, Mapi Group, Lyon, France; Nizar M. Tannir, University of Texas MD Anderson Cancer Center Hospital, Houston; Hans J. Hammers, University of Texas Southwestern Medical Center; Thomas E. Hutson, Texas Oncology-Baylor Sammons Cancer Center, Dallas, TX; Thomas Powles, Queen Mary University of London, London, United Kingdom; Frede Donskov, Aarhus University Hospital, Aarhus, Denmark; Katriina Peltola, Helsinki University Hospital Cancer Center, Helsinki, Finland; Manuela Schmidinger, Medical University of Vienna, Vienna, Austria; Daniel Y.C. Heng, University of Calgary, Calgary, Alberta, Canada; Paul N. Mainwaring, Icon Cancer Care, Brisbane, Queensland, Australia; Jae Lyun Lee, University of Ulsan College of Medicine, Seoul, South Korea; Bruce J. Roth, Washington University in St Louis, St Louis, MO; John Baer, Milan Mangeshkar, and Christian Scheffold, Exelixis, South San Francisco; Sumanta Pal, City of Hope National Medical Center, Duarte, CA; Robert J. Motzer, Memorial Sloan Kettering Cancer Center, New York, NY; and Toni K. Choueiri, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.75.2170DOI Listing
March 2018

Setting Research Priorities for Kidney Cancer.

Eur Urol 2017 12 8;72(6):861-864. Epub 2017 May 8.

Departments of Surgery and Surgical Oncology (Division of Urology), Princess Margaret Cancer Centre, University Health Network, and the University of Toronto, Toronto, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2017.04.011DOI Listing
December 2017

Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study.

J Clin Oncol 2017 Dec 5;35(34):3851-3858. Epub 2017 Jul 5.

Hans J. Hammers, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD; Elizabeth R. Plimack, Fox Chase Cancer Center, Philadelphia, PA; Jeffrey R. Infante, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Brian I. Rini, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; David F. McDermott, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Boston, MA; Lionel D. Lewis, The Geisel School of Medicine and The Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, NH; Martin H. Voss, Memorial Sloan Kettering Cancer Center, New York, NY; Padmanee Sharma, MD Anderson Cancer Center, University of Texas, Houston, TX; Sumanta K. Pal, City of Hope Comprehensive Cancer Center, Duarte, CA; Albiruni R. Abdul Razak, Princess Margaret Cancer Centre, Toronto, Ontario; Christian Kollmannsberger, British Columbia Cancer Agency, Vancouver, British Columbia; Daniel Y.C. Heng, Tom Baker Cancer Center, University of Calgary, Calgary; Jennifer Spratlin, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada; M. Brent McHenry, Bristol-Myers Squibb, Princeton, NJ; and Asim Amin, Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.72.1985
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.72.1985DOI Listing
December 2017

In Reply.

Oncologist 2017 12 11;22(12):1561. Epub 2017 Sep 11.

Departments of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2017-0283DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5728026PMC
December 2017

Adjuvant therapy in renal cell carcinoma.

Cancer Treat Rev 2017 Nov 23;60:152-157. Epub 2017 Sep 23.

Department of Medical Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2017.09.004DOI Listing
November 2017

Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.

J Clin Oncol 2017 Sep 23;35(26):2993-3001. Epub 2017 Jun 23.

Toni K. Choueiri, Dana-Farber Cancer Institute, Boston; Melanie M. Frigault, Edwin A. Clark, Amir A. Handzel, and Humphrey Gardner, AstraZeneca, Waltham, MA; Elizabeth Plimack, Fox Chase Cancer Center, Philadelphia, PA; Eric Jonasch, MD Anderson Cancer Center, Houston, TX; Sumanta Kumar Pal, City of Hope, Duarte, CA; Hendrik-Tobias Arkenau, Sarah Cannon Research Institute, University College London Cancer Institute; Thomas Powles, Barts Cancer Institute, London; Shethah Morgan, AstraZeneca, Cambridge, United Kingdom; Daniel Y.C. Heng, Tom Baker Cancer Center, Calgary, Alberta, Canada; and Laurence Albiges, Institute Gustave Roussy, Paris, France.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.72.2967
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.72.2967DOI Listing
September 2017

Renal Medullary Carcinoma.

Authors:
Daniel Y C Heng

J Oncol Pract 2017 07;13(7):422-423

Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.2017.023812DOI Listing
July 2017

On-treatment biomarkers in metastatic renal cell carcinoma: towards individualization of prognosis?

Expert Rev Anticancer Ther 2017 02 20;17(2):97-99. Epub 2016 Dec 20.

c Cleveland Clinic , Taussig Cancer Institute , Cleveland , OH , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737140.2017.1269605DOI Listing
February 2017

The next 10 years: Challenges for the future and overcoming resistance to targeted therapies for renal cell carcinoma.

Authors:
Daniel Y C Heng

Can Urol Assoc J 2016 Nov-Dec;10(11-12Suppl7):S256-S258

Tom Baker Cancer Centre, Calgary, and Department of Medicine, University of Calgary, Calgary, AB, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5489/cuaj.4294DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215305PMC
January 2017

Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience.

Ther Adv Urol 2016 Dec 16;8(6):338-347. Epub 2016 Aug 16.

Tom Baker Cancer Center, Alberta Health Services Cancer Care, University of Calgary, 1331 29th St NW, Calgary, Alberta, Canada T2N 4N2.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1756287216663073DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5117166PMC
December 2016

Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.

Cancer Treat Rev 2016 Nov 10;50:109-117. Epub 2016 Sep 10.

Institut Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2016.09.002DOI Listing
November 2016

Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations.

J Clin Oncol 2016 Oct;34(30):3655-3663

Laurence Albiges, Wanling Xie, Rana R. McKay, Andre P. Fay, Guillermo de Velasco, Sabina Signoretti, and Toni K. Choueiri, Dana-Farber Cancer Institute; Wanling Xie, Rana R. McKay, Mark A. Preston, Eunyoung Cho, Sabina Signoretti, and Toni K. Choueiri, Brigham and Women's Hospital; Laurence Albiges, Wanling Xie, Rana R. McKay, Andre P. Fay, Guillermo de Velasco, Eunyoung Cho, David F. McDermott, Sabina Signoretti, and Toni K. Choueiri, Harvard Medical School; Mark A. Preston and Kathryn M. Wilson, Harvard School of Public Health; David F. McDermott, Beth Israel Deaconess Medical Center, Boston, MA; Laurence Albiges, Gustave Roussy, Université Paris-Saclay, Villejuif, France; A. Ari Hakimi, Emily C. Zabor, Anders J. Skanderup, and Helena Furberg, Memorial Sloan Kettering Cancer Center, New York; Ronit Simantov and Xun Lin, Pfizer Oncology, New York, NY; Jae-Lyun Lee, University of Ulsan College of Medicine, Asan; Sun-Young Rha, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea; Brian I. Rini, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; Sandy Srinivas, Stanford Cancer Institute, Stanford; Sumanta K. Pal, City of Hope Comprehensive Cancer Center, Duarte, CA; Georg A. Bjarnason, Sunnybrook Odette Cancer Center, Toronto; Scott Ernst, London Health Sciences Center, London, Ontario; Lori A. Wood, Queen Elizabeth II Health Sciences Center, Halifax, Nova Scotia; Daniel Y.C. Heng, Tom Baker Cancer Center; University of Calgary, Calgary, Alberta, Canada; Ulka N. Vaishamayan, Karmanos Cancer Center, Detroit, MI; Neeraj Agarwal, University of Utah Huntsman Cancer Institute, Salt Lake City, UT; Takeshi Yuasa, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan; Aristotelis Bamias, Alexandra Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece; and Eunyoung Cho, The Warren Alpert Medical School of Brown University; Brown University School of Public Health, Providence, RI.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.66.7311DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5065111PMC
October 2016

Disease characteristics and survival outcomes of extragonadal primary germ cell tumour in two Canadian tertiary cancer centres.

Can Urol Assoc J 2016 May-Jun;10(5-6):E165-E170. Epub 2016 May 12.

Department of Medical Oncology, Tom Baker Cancer Centre, Calgary, AB, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5489/cuaj.3357DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5065405PMC
May 2016

The evolving landscape of metastatic renal cell carcinoma.

Am Soc Clin Oncol Educ Book 2012 :299-302

From the Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada; Dana Farber Cancer Institute and Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2012.32.299DOI Listing
April 2016

Contemporary Treatment of Metastatic Renal Cell Carcinoma.

Oncol Rev 2016 Apr 1;10(1):295. Epub 2016 Jul 1.

Department of Medical Oncology, Tom Baker Cancer Centre, University of Calgary , Calgary, AB, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4081/oncol.2016.295DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4943094PMC
April 2016

Review of the Interaction Between Body Composition and Clinical Outcomes in Metastatic Renal Cell Cancer Treated With Targeted Therapies.

J Kidney Cancer VHL 2016 22;3(1):12-22. Epub 2016 Mar 22.

Department of Oncology, University of Calgary, Tom Baker Cancer Centre, Calgary, Alberta, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.15586/jkcvhl.2016.45DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345526PMC
March 2016

Conditional Survival of Patients With Metastatic Testicular Germ Cell Tumors Treated With First-Line Curative Therapy.

J Clin Oncol 2016 Mar 19;34(7):714-20. Epub 2016 Jan 19.

Jenny J. Ko, Abbotsford Cancer Agency, Abbotsford, British Columbia; Haocheng Li, University of Calgary; Igor Stukalin, Nimira Alimohamed, and Daniel Y.C. Heng, Tom Baker Cancer Center, Calgary, Alberta; Tehmina Asif, Saskatchewan Cancer Agency, Saskatoon, Saskatchewan; Daphne Day and Philippe L. Bedard, Princess Margaret Cancer Center, Toronto, Ontario, Canada; Brandon Bernard and Christopher J. Sweeney, Dana Farber Cancer Institute, Boston, MA; and Ben Tran and Margaret Lee, Royal Melbourne Hospital, Parkville, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.7909DOI Listing
March 2016

Statins and survival outcomes in patients with metastatic renal cell carcinoma.

Eur J Cancer 2016 Jan 11;52:155-62. Epub 2015 Dec 11.

Department of Medical Oncology, Tom Baker Cancer Center, 1331 29 Street Northwest, Calgary, AB T2N 4N2, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2015.10.008DOI Listing
January 2016

The use of prognostic factors in metastatic renal cell carcinoma.

Urol Oncol 2015 Dec 8;33(12):509-16. Epub 2015 Sep 8.

Department of Medical Oncology, Tom Baker Cancer Center, University of Calgary, Calgary, Alberta, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2015.08.003DOI Listing
December 2015

Metastatic renal cell carcinoma: Contending with a sea change in therapy.

Urol Oncol 2015 Dec;33(12):507-8

Department of Medical Oncology, University of Calgary, Tom Baker Cancer Center, Calgary, AB.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2015.10.005DOI Listing
December 2015

Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma.

Eur J Cancer 2015 Nov 4;51(17):2580-6. Epub 2015 Sep 4.

Kidney Cancer Center, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School, Boston, United States; Kidney Cancer Program, Dana-Farber Harvard Cancer Center, Boston, United States. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09598049150080
Publisher Site
http://dx.doi.org/10.1016/j.ejca.2015.08.017DOI Listing
November 2015

Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma.

N Engl J Med 2015 Nov 25;373(19):1814-23. Epub 2015 Sep 25.

From the Dana-Farber Cancer Institute, Boston (T.K.C., P.W.K.); Institut Gustave Roussy, Villejuif, France (B.E.); Barts Cancer Institute, Cancer Research UK Experimental Cancer Medicine Centre, Queen Mary University of London, Royal Free NHS Trust, London (T.P.); Icon Cancer Care, South Brisbane, QLD, Australia (P.N.M.); Cleveland Clinic, Cleveland (B.I.R.); Aarhus University Hospital, Aarhus, Denmark (F.D.); Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore (H.H.); Texas Oncology-Charles A. Sammons Cancer Center, Baylor University, Dallas (T.E.H.); University of Ulsan College of Medicine (J.-L.L.) and Seoul National University Hospital (B.K.) - both in Seoul, South Korea; Helsinki University Central Hospital Cancer Center, Helsinki (K.P.); Washington University in St. Louis, St. Louis (B.J.R.); Sunnybrook Odette Cancer Centre, Toronto (G.A.B.), and Tom Baker Cancer Centre, Calgary, AB (D.Y.C.H.) - both in Canada; National Institute of Oncology, Budapest, Hungary (L.G.); Hospital de la Santa Creu i Sant Pau, Barcelona (P.M.); Medical University of Vienna, Vienna (M.S.); Exelixis, South San Francisco, CA (A.B-H., C.H., C.S., G.M.S.); University of Texas M.D. Anderson Cancer Center, Houston (N.M.T.); and the Memorial Sloan Kettering Cancer Center, New York (R.J.M.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1510016DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024539PMC
November 2015

Third-line treatment in metastatic renal cell carcinoma and bone metastases.

Authors:
Daniel Y C Heng

Can Urol Assoc J 2015 Jul-Aug;9(7-8):268

University of Calgary, Tom Baker Cancer Center, Calgary, AB.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5489/cuaj.3238DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4537339PMC
August 2015

New molecular targets in non clear renal cell carcinoma: An overview of ongoing clinical trials.

Cancer Treat Rev 2015 Jul 15;41(7):614-22. Epub 2015 May 15.

Section of Pathological Anatomy, Polytechnic University of the Marche Region, School of Medicine, AOU Ospedali Riuniti, Ancona, Italy.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03057372150010
Publisher Site
http://dx.doi.org/10.1016/j.ctrv.2015.05.006DOI Listing
July 2015

Comparison of oncology drug approval between Health Canada and the US Food and Drug Administration.

Cancer 2015 May 20;121(10):1688-93. Epub 2015 Jan 20.

Department of Oncology, Tom Baker Cancer Center, Calgary, Alberta, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.29246DOI Listing
May 2015

The promise of futility trials in neurological diseases.

Nat Rev Neurol 2015 May 17;11(5):300-5. Epub 2015 Mar 17.

Department of Clinical Neurosciences, Foothills Hospital, University of Calgary, 1403 29th Street NW, Calgary, AB T2N 2T9, Canada.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/nrneurol.2015.34
Publisher Site
http://dx.doi.org/10.1038/nrneurol.2015.34DOI Listing
May 2015

Outcomes with abiraterone acetate in metastatic castration-resistant prostate cancer patients who have poor performance status.

Eur Urol 2015 Mar 31;67(3):441-7. Epub 2014 Jan 31.

Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2014.01.030DOI Listing
March 2015

Sunitinib in the treatment of advanced solid tumors.

Recent Results Cancer Res 2014 ;201:165-84

Medical Oncology, Tom Baker Cancer Center, Calgary, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-642-54490-3_9DOI Listing
September 2014

Current management and future perspectives of metastatic renal cell carcinoma.

Int J Urol 2014 Sep 27;21(9):847-55. Epub 2014 May 27.

Tom Baker Cancer Center, Calgary, Alberta, Canada.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/iju.12502
Publisher Site
http://dx.doi.org/10.1111/iju.12502DOI Listing
September 2014

Management of metastatic kidney cancer in the era of personalized medicine.

Crit Rev Clin Lab Sci 2014 Apr 22;51(2):85-97. Epub 2014 Jan 22.

Department of Medical Oncology, Tom Baker Cancer Center, University of Calgary , Calgary, AB , Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10408363.2013.869544DOI Listing
April 2014

Considerations for the design of future clinical trials in metastatic renal cell carcinoma.

Clin Genitourin Cancer 2014 Feb 9;12(1):1-12. Epub 2013 Nov 9.

IRCCS San Matteo University Hospital Foundation, Pavia, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2013.07.004DOI Listing
February 2014

Programmed death 1 pathway inhibition in metastatic renal cell cancer and prostate cancer.

Curr Oncol Rep 2013 Apr;15(2):98-104

Tom Baker Cancer Center, University of Calgary, Calgary, AB, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-012-0284-2DOI Listing
April 2013

Impact of body composition on clinical outcomes in metastatic renal cell cancer.

Oncologist 2011 21;16(11):1484-6. Epub 2011 Oct 21.

Department of Oncology, University of Calgary, Tom Baker Cancer Centre, Calgary, Alberta, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1634/theoncologist.2011-0337DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3233281PMC
June 2012

The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor-targeted therapy.

Cancer 2012 Jan 29;118(2):365-70. Epub 2011 Jun 29.

Department of Medical Oncology, Vancouver Cancer Centre, British Columbia Cancer Agency, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.26201DOI Listing
January 2012

Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib.

J Clin Oncol 2011 Sep 1;29(25):3450-6. Epub 2011 Aug 1.

Dana-Farber Cancer Institute, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2010.34.4309DOI Listing
September 2011

Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far.

Hematol Oncol Clin North Am 2011 Aug;25(4):871-91

Department of Oncology, Tom Baker Cancer Center, University of Calgary, 1331-29th Street North West, Calgary, Alberta, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2011.04.003DOI Listing
August 2011

Combination therapy in metastatic renal cell carcinoma.

Authors:
Daniel Y C Heng

Lancet Oncol 2011 Jul 12;12(7):613-4. Epub 2011 Jun 12.

Department of Oncology, Tom Baker Cancer Center, University of Calgary, Calgary, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(11)70146-2DOI Listing
July 2011

Sunitinib rechallenge in metastatic renal cell carcinoma patients.

Cancer 2010 Dec 2;116(23):5400-6. Epub 2010 Nov 2.

Department of Solid Tumor Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio 44195, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/cncr.25583
Publisher Site
http://dx.doi.org/10.1002/cncr.25583DOI Listing
December 2010

Prognostic and predictive biomarkers in renal cell carcinoma.

Target Oncol 2010 Jun 28;5(2):85-94. Epub 2010 Jun 28.

Department of Oncology, Tom Baker Cancer Centre, University of Calgary, 1331 - 29th Street NW, Calgary, AB, T2N 4N2, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11523-010-0143-8DOI Listing
June 2010

Sunitinib.

Recent Results Cancer Res 2010 ;184:71-82

BC Cancer Agency, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-642-01222-8_6DOI Listing
March 2010

Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions.

Ther Adv Med Oncol 2010 Jan;2(1):39-49

BC Cancer Agency, 600 West 12 Avenue, Vancouver, British Columbia, V5Z 4E6, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758834009352498DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3126007PMC
January 2010

Non-clear cell renal cancer: features and medical management.

J Natl Compr Canc Netw 2009 Jun;7(6):659-65

Tom Baker Cancer Center, Calgary, Alberta, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2009.0046DOI Listing
June 2009

Anti-angiogenic targets in the treatment of advanced renal cell carcinoma.

Curr Cancer Drug Targets 2008 Dec;8(8):676-82

Experimental Therapeutics, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH 44106, USA.

View Article

Download full-text PDF

Source
December 2008